Main Street Research LLC Has $40.96 Million Stock Holdings in Boston Scientific Corporation $BSX

Main Street Research LLC grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 2.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 381,293 shares of the medical equipment provider’s stock after acquiring an additional 8,518 shares during the quarter. Boston Scientific accounts for 2.5% of Main Street Research LLC’s holdings, making the stock its 20th biggest position. Main Street Research LLC’s holdings in Boston Scientific were worth $40,955,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of BSX. Brighton Jones LLC boosted its position in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. D.A. Davidson & CO. boosted its position in Boston Scientific by 4.6% during the 1st quarter. D.A. Davidson & CO. now owns 11,536 shares of the medical equipment provider’s stock worth $1,164,000 after acquiring an additional 504 shares during the last quarter. OneDigital Investment Advisors LLC boosted its position in Boston Scientific by 14.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 10,843 shares of the medical equipment provider’s stock worth $1,094,000 after acquiring an additional 1,371 shares during the last quarter. Concurrent Investment Advisors LLC boosted its position in Boston Scientific by 36.0% during the 1st quarter. Concurrent Investment Advisors LLC now owns 13,245 shares of the medical equipment provider’s stock worth $1,336,000 after acquiring an additional 3,509 shares during the last quarter. Finally, Penserra Capital Management LLC boosted its position in Boston Scientific by 128.3% during the 1st quarter. Penserra Capital Management LLC now owns 8,811 shares of the medical equipment provider’s stock worth $888,000 after acquiring an additional 4,952 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.2%

BSX opened at $98.79 on Wednesday. Boston Scientific Corporation has a 1-year low of $84.13 and a 1-year high of $109.50. The stock’s fifty day simple moving average is $100.48 and its 200 day simple moving average is $102.45. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a market cap of $146.38 billion, a PE ratio of 52.83, a price-to-earnings-growth ratio of 2.02 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the prior year, the business earned $0.63 EPS. The firm’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on BSX shares. Raymond James Financial upped their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Erste Group Bank cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Needham & Company LLC reiterated a “buy” rating and set a $121.00 price objective on shares of Boston Scientific in a research note on Friday, October 17th. Finally, Truist Financial upped their price objective on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $123.77.

Insiders Place Their Bets

In other Boston Scientific news, Director Ellen M. Zane sold 2,901 shares of the stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $102.24, for a total transaction of $296,598.24. Following the transaction, the director owned 24,134 shares in the company, valued at $2,467,460.16. This trade represents a 10.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 162,891 shares of company stock worth $16,475,387. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.